Evidence map›Paper›PMID 10613996›Full record

Trial reportJournal of thrombosis and thrombolysis2000

High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.

D J Kereiakes, T M Broderick, E M Roth, D Whang, M Mueller, P Lacock, L C Anderson, W Howard, C Blanck, J Schneider and 1 more

Abstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

D J KereiakesThe Carl and Edyth Lindner Center for Clinical Cardiovascular Research, Cincinnati, Ohio 45219, USA. lindner@healthall.com.
T M Broderick
E M Roth
D Whang
M Mueller
P Lacock
L C Anderson
W Howard
C Blanck
J Schneider
C A Abbottsmith
Center for Clinical Research (United States) · USChrist Hospital · USCommunity Health Alliance · USOhio Heart & Vascular Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of platelet aggregation provided by abciximab, eptifibatide, and tirofiban as part of a randomized, comparative trial of these agents on platelet function in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Platelet count <350 K/microL in PRP reduced measured platelet inhibition by abciximab, but not eptifibatide nor tirofiban. This observation suggests the need for standardized, uniform platelet counts in PRP during future comparisons of the degree of platelet inhibition by these agents.

Indexed as

AbciximabAngina, UnstableAntibodies, MonoclonalConfounding Factors, EpidemiologicEptifibatideFemaleHumansImmunoglobulin Fab FragmentsMalePeptidesPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet CountPlatelet Function TestsPlatelet Glycoprotein GPIIb-IIIa ComplexTirofibanAbciximabAntibodies, MonoclonalEptifibatideImmunoglobulin Fab FragmentsPeptidesPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexTirofibanTyrosine

Identifiers

PMID10613996
OpenAlexW110532004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.